Two River Group

Candid Therapeutics is a biotechnology company specializing in the development of innovative therapies for immunological disorders. The company's primary focus is on creating novel, user-friendly treatments for autoimmune diseases. Their core technology involves advanced T-cell engager antibodies, which precisely redirect T-cells to selectively eliminate autoreactive B-cells, aiming to deliver transformative efficacy and improved therapeutic outcomes for patients.

ByHeart, Inc. is a New York-based company specializing in the development of infant and baby nutritional food products. Founded in 2016, ByHeart focuses on creating formulas and foods that support various aspects of babies' health, including immune, microbiome, cognitive, and digestive health. The company emphasizes the use of hand-picked ingredients and small-batch blending to ensure high-quality, nutritious options for young children. ByHeart aims to translate advanced nutrition science and breastmilk research into innovative products that provide parents with peace of mind while proactively fostering a strong foundation for their babies’ future health. The company operates facilities in Pennsylvania, reinforcing its commitment to quality and safety in infant nutrition.

ByHeart, Inc. is a New York-based company specializing in the development of infant and baby nutritional food products. Founded in 2016, ByHeart focuses on creating formulas and foods that support various aspects of babies' health, including immune, microbiome, cognitive, and digestive health. The company emphasizes the use of hand-picked ingredients and small-batch blending to ensure high-quality, nutritious options for young children. ByHeart aims to translate advanced nutrition science and breastmilk research into innovative products that provide parents with peace of mind while proactively fostering a strong foundation for their babies’ future health. The company operates facilities in Pennsylvania, reinforcing its commitment to quality and safety in infant nutrition.

IconOVir Bio is a preclinical-stage biotechnology company focused on developing innovative oncolytic virus therapies for cancer treatment. The company's proprietary platform aims to overcome the limitations associated with first- and second-generation oncolytic viruses, thereby enhancing the therapeutic options available to healthcare professionals. By prioritizing personalized therapy, IconOVir Bio seeks to improve treatment outcomes for cancer patients, positioning itself at the forefront of advancements in oncology.

Neogene Therapeutics, Inc. is a biotechnology company based in New York, founded in 2018, that focuses on developing T cell therapies for cancer treatment. The company specializes in creating personalized engineered T cells that target neo-antigens, which are mutated proteins present in cancer cells due to DNA mutations. By leveraging advanced technologies, Neogene isolates T cell receptor (TCR) genes specific to these neo-antigens from tumor biopsies routinely collected from patients. This process utilizes high-sensitivity DNA sequencing and genetic screening to identify TCRs that can effectively recognize and attack cancer cells. Neogene's innovative approach aims to enhance the precision and efficacy of cancer therapies, offering improved treatment options for patients facing a broad spectrum of cancers.

ByHeart, Inc. is a New York-based company specializing in the development of infant and baby nutritional food products. Founded in 2016, ByHeart focuses on creating formulas and foods that support various aspects of babies' health, including immune, microbiome, cognitive, and digestive health. The company emphasizes the use of hand-picked ingredients and small-batch blending to ensure high-quality, nutritious options for young children. ByHeart aims to translate advanced nutrition science and breastmilk research into innovative products that provide parents with peace of mind while proactively fostering a strong foundation for their babies’ future health. The company operates facilities in Pennsylvania, reinforcing its commitment to quality and safety in infant nutrition.

Amunix Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering and developing innovative protein and peptide therapeutics aimed at treating cancer. The company employs several proprietary platforms, including XTEN for extending drug half-life, XPAT for analyzing protease activity in the tumor microenvironment, and ProTIA, which focuses on immuno-oncology therapeutics. Amunix's product pipeline includes prodrugs and transformative T-cell engagers designed to activate the immune system against solid tumors. The company collaborates with various academic, biotechnology, and pharmaceutical sectors, maintaining strategic partnerships with organizations such as Janssen and Biogen-Idec. Founded in 2006 and headquartered in Mountain View, California, Amunix strives to deliver breakthroughs that can harness the immune system to combat cancer more effectively.

Kronos Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative cancer therapeutics. Founded in 2017 and headquartered in San Mateo, California, the company focuses on targeting dysregulated transcription factors and oncogenic signaling pathways. Its lead candidate, entospletinib, is a selective inhibitor of spleen tyrosine kinase aimed at treating acute myeloid leukemia. Additionally, Kronos Bio is developing KB-0742, an orally bioavailable inhibitor of cyclin-dependent kinase 9, intended for MYC-amplified solid tumors. By leveraging advanced technologies such as high-throughput small-molecule microarrays and targeted protein degradation, Kronos Bio aims to identify effective compounds that can modulate historically undruggable cancer targets, ultimately striving to improve patient outcomes through precision medicine.

2 out of 3 men will start to lose their hair by the age of 35 - but the earlier you take action, the more hair you keep. Keeps is a full-service healthcare company focused exclusively on helping men keep their hair. From expert diagnosis to affordable treatment, patient support to education, Keeps provides a regimen specific to each customer's condition through a seamless digital experience, allowing men to manage hair loss from start to finish. Keeps’ licensed physicians review each customer's information in order to identify and prescribe a unique treatment plan of FDA-approved products, and we sell them at half the price customers would pay at their local pharmacy. With Keeps, customers receive exactly what they need, and nothing they don’t. Keeps is the first brand from Thirty Madison, which is rebuilding the healthcare experience for the modern consumer.

Thirty Madison, Inc. is a digital health company based in Astoria, New York, that focuses on providing specialized healthcare solutions for patients with chronic conditions. Founded in 2016, the company operates several condition-specific brands, including Keeps, which offers a subscription-based service for men’s hair loss prevention; Cove, which provides online consultations and prescriptions for migraine treatment; Picnic, targeting allergies; Facet for skin conditions; and NURX for sexual health. Each brand is designed to address the unique needs of its community, offering personalized treatments and support. Thirty Madison emphasizes a human-centered approach, empowering individuals with accessible and effective healthcare solutions tailored to their ongoing conditions.

Willow is stylish affordable disposable underwear that offers comfort, confidence, and leak-free protection, delivered discreetly to your door at a fraction of the price. Current options on the market are either expensive or bulky and generally lacking in style — plus, you have to purchase them at the store. Willow’s product is the thinnest and most absorbent on the market, and has better odor control than other products. It’s extremely "breathable” and wicks liquid away from skin, just like sportswear. Best of all, Willow’s stylish products cost less than others because they are sold directly to the consumer, with no mark up by stores.

See, Easy. We believe buying contact lenses and glasses should be simple. Full stop. That’s why our goal is to deliver the easiest, most hassle-free contact lens and glasses experience in the world. Here’s how we see it at Hubble Contacts. If you’re spending all your time arguing with customer service reps, endlessly searching for the right pair of glasses, or trying to remember to reorder your contacts before they run out (again), you’re not focused on all the things the world has to offer. Like that incredible sunset outside your window, the text convos on your phone that make you laugh (until you cry), or the gummy, toothless grin smiling at you from across her highchair. Hubble Contacts was created out of the desire to make contact lenses accessible and affordable to as many people as possible. Over the years, we have continued to evolve and adapt to the changing needs of our customers, and expand our product line along the way to also include high quality eyeglasses and sunglasses. With a passion for eye care and a dedication to customer service, our mission remains making a difference in the industry. So, let Hubble’s world-class team take care of you — and your contacts and glasses. And you? You keep your eyes on the prize.

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing off-the-shelf, genetically engineered allogeneic T cell therapies for cancer treatment. The company's pipeline includes UCART19, in development for relapsed/refractory acute lymphoblastic leukemia, and several preclinical allogeneic CAR T therapies targeting various cancers. Allogene's approach uses gene editing and advanced manufacturing technologies to create a scalable, broader patient eligibility option compared to autologous therapies. Revenue is primarily generated through collaborations and licensing agreements.

Andie Co. is an online retailer based in New York that specializes in women's swimwear. Founded in 2016, the company designs and manufactures a range of products, including one-piece and two-piece swimsuits, as well as accessories and gift cards. Operating as a direct-to-consumer brand, Andie eliminates retail middlemen, allowing women to purchase high-quality, fashionable swimwear at accessible prices. The company's eCommerce platform provides a convenient shopping experience, enabling customers to try on swimsuits at home and find the perfect fit. By focusing on luxurious designs and affordability, Andie offers a compelling alternative in the swimwear market.

See, Easy. We believe buying contact lenses and glasses should be simple. Full stop. That’s why our goal is to deliver the easiest, most hassle-free contact lens and glasses experience in the world. Here’s how we see it at Hubble Contacts. If you’re spending all your time arguing with customer service reps, endlessly searching for the right pair of glasses, or trying to remember to reorder your contacts before they run out (again), you’re not focused on all the things the world has to offer. Like that incredible sunset outside your window, the text convos on your phone that make you laugh (until you cry), or the gummy, toothless grin smiling at you from across her highchair. Hubble Contacts was created out of the desire to make contact lenses accessible and affordable to as many people as possible. Over the years, we have continued to evolve and adapt to the changing needs of our customers, and expand our product line along the way to also include high quality eyeglasses and sunglasses. With a passion for eye care and a dedication to customer service, our mission remains making a difference in the industry. So, let Hubble’s world-class team take care of you — and your contacts and glasses. And you? You keep your eyes on the prize.

See, Easy. We believe buying contact lenses and glasses should be simple. Full stop. That’s why our goal is to deliver the easiest, most hassle-free contact lens and glasses experience in the world. Here’s how we see it at Hubble Contacts. If you’re spending all your time arguing with customer service reps, endlessly searching for the right pair of glasses, or trying to remember to reorder your contacts before they run out (again), you’re not focused on all the things the world has to offer. Like that incredible sunset outside your window, the text convos on your phone that make you laugh (until you cry), or the gummy, toothless grin smiling at you from across her highchair. Hubble Contacts was created out of the desire to make contact lenses accessible and affordable to as many people as possible. Over the years, we have continued to evolve and adapt to the changing needs of our customers, and expand our product line along the way to also include high quality eyeglasses and sunglasses. With a passion for eye care and a dedication to customer service, our mission remains making a difference in the industry. So, let Hubble’s world-class team take care of you — and your contacts and glasses. And you? You keep your eyes on the prize.

See, Easy. We believe buying contact lenses and glasses should be simple. Full stop. That’s why our goal is to deliver the easiest, most hassle-free contact lens and glasses experience in the world. Here’s how we see it at Hubble Contacts. If you’re spending all your time arguing with customer service reps, endlessly searching for the right pair of glasses, or trying to remember to reorder your contacts before they run out (again), you’re not focused on all the things the world has to offer. Like that incredible sunset outside your window, the text convos on your phone that make you laugh (until you cry), or the gummy, toothless grin smiling at you from across her highchair. Hubble Contacts was created out of the desire to make contact lenses accessible and affordable to as many people as possible. Over the years, we have continued to evolve and adapt to the changing needs of our customers, and expand our product line along the way to also include high quality eyeglasses and sunglasses. With a passion for eye care and a dedication to customer service, our mission remains making a difference in the industry. So, let Hubble’s world-class team take care of you — and your contacts and glasses. And you? You keep your eyes on the prize.

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that specializes in the development of innovative therapies for dermatological conditions. The company focuses on immunology and inflammation, targeting specific pathways in the skin. Its lead product candidates include SNA-120, a first-in-class inhibitor currently undergoing Phase IIb clinical trials for psoriasis and associated itching, and SNA-125, a dual Janus kinase 3 inhibitor in Phase I/II trials aimed at treating atopic dermatitis and psoriasis. Additionally, Sienna is developing SNA-001, a topical silver particle suspension in pivotal trials for acne treatment and the reduction of light-pigmented hair. Founded in 2010 and headquartered in Westlake Village, California, Sienna Biopharmaceuticals has experienced significant operational challenges, filing for Chapter 11 bankruptcy in 2019, which was later converted to Chapter 7. The company, previously known as Sienna Labs, Inc., rebranded in February 2016 to better reflect its focus on dermatology and aesthetics.

Cell Design Labs, Inc. is a biotherapeutics company based in San Francisco, California, focused on developing innovative cell-based therapies for cancer and other serious diseases. Established in 2015, the company aims to harness the immune system's capabilities to create advanced treatments that offer improved power, precision, safety, and durability. Cell Design Labs specializes in disruptive T cell receptor therapies, which modify the body's immune cells to specifically recognize and eliminate malignant cells. This approach enables researchers to efficiently develop effective cell-based therapies that address some of the most challenging medical conditions. The company operates as a subsidiary of Gilead Sciences, Inc.

See, Easy. We believe buying contact lenses and glasses should be simple. Full stop. That’s why our goal is to deliver the easiest, most hassle-free contact lens and glasses experience in the world. Here’s how we see it at Hubble Contacts. If you’re spending all your time arguing with customer service reps, endlessly searching for the right pair of glasses, or trying to remember to reorder your contacts before they run out (again), you’re not focused on all the things the world has to offer. Like that incredible sunset outside your window, the text convos on your phone that make you laugh (until you cry), or the gummy, toothless grin smiling at you from across her highchair. Hubble Contacts was created out of the desire to make contact lenses accessible and affordable to as many people as possible. Over the years, we have continued to evolve and adapt to the changing needs of our customers, and expand our product line along the way to also include high quality eyeglasses and sunglasses. With a passion for eye care and a dedication to customer service, our mission remains making a difference in the industry. So, let Hubble’s world-class team take care of you — and your contacts and glasses. And you? You keep your eyes on the prize.

UroGen Pharma Ltd. is a clinical-stage biopharmaceutical company based in Princeton, New Jersey, focused on developing innovative therapies for specialty cancers and urologic diseases. The company is dedicated to transforming the standard of care in uro-oncology through its diverse pipeline of product candidates. Its lead products, including UGN-101 and UGN-102, aim to ablate tumors non-surgically and address various forms of non-muscle invasive urothelial cancer, such as low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. UroGen is also advancing UGN-201, an immunotherapy candidate targeting high-grade non-muscle invasive bladder cancer. Furthermore, the company's proprietary RTGel technology enhances drug delivery by enabling sustained release, improving therapeutic efficacy. UroGen has established licensing agreements with Allergan Pharmaceuticals for the development of RTGel-based products and with Agenus Inc. to commercialize treatments for urinary tract cancers. Founded in 2004, UroGen Pharma continues to innovate in the field of urology and oncology.

Kite Pharma is a clinical-stage biotechnology company focused on developing innovative immune-based therapies for various cancer indications. The company is dedicated to designing and advancing proprietary product candidates that leverage the patient's immune system to combat tumor cells. By harnessing the potential of cell therapy, Kite Pharma aims to provide effective treatment options and improve the management of a wide range of cancer types, offering new strategies in the fight against this disease.

Kite Pharma is a clinical-stage biotechnology company focused on developing innovative immune-based therapies for various cancer indications. The company is dedicated to designing and advancing proprietary product candidates that leverage the patient's immune system to combat tumor cells. By harnessing the potential of cell therapy, Kite Pharma aims to provide effective treatment options and improve the management of a wide range of cancer types, offering new strategies in the fight against this disease.